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Leaky transporters and sphincters in Barrett’s oesophagus?
Barrett’s oesophagus is a metaplastic epithelial 
condition caused by chronic gastro-oesophageal reﬂ ux 
that predisposes to development of oesophageal 
adenocarcinoma. Barrett’s oesophagus and oesophageal 
adenocarcinoma are not often thought of as hereditary 
diseases—ie, a positive family history of either disease 
in ﬁ rst-degree relatives or probands is usually not 
obtained.1 However, since these diseases could be 
polygenic in origin, with each locus contributing 
only weakly to disease development, clinical family 
history might underestimate the hereditary genetic 
component. Estimates suggest that 24% of cases of 
oesophageal adenocarcinoma are hereditary and 76% 
are sporadic,2 whereas up to 35% of cases of Barrett’s 
oesophagus have a hereditary genetic component.3 
Therefore, several research groups have sought to 
identify disease loci using genome-wide association 
studies. 
Su and colleagues4 reported an association between 
Barrett’s oesophagus and variants at the MHC locus 
and at chromosome 16q24.1. Similarly, Levine and 
co-workers5 identiﬁ ed associated loci in the gene 
CRTC1 at 19p13, in BARX1 at 9q22, and near FOXP1 at 
3p14. Subsequently, single nucleotide polymorphisms 
(SNPs) within the CDKN2A and TP53 tumour suppressor 
genes were reported to associate with oesophageal 
adenocarcinoma.6 Palles and colleagues7 identiﬁ ed 
an association between Barrett’s oesophagus and 
polymorphisms near the genes TBX5 (2p24) and GDF7 
(12q24), and between both Barrett’s oesophagus 
and oesophageal adenocarcinoma and a locus within 
ALDH1A2 (15q21.2). In a focused analysis of 16 genes 
coding for the androgen pathway,8 associations were 
noted between Barrett’s oesophagus and SNPs 
within CYP17A1 (10q24.32), and between oesophageal 
adenocarcinoma and JMJD1C (10q21.3). Prioritising 
this broad array of loci across multiple studies has 
been diﬃ  cult. In a review and meta-analysis of existing 
data,9 17 germline markers of susceptibility to Barrett’s 
oesophagus were identiﬁ ed, in addition to ﬁ ve somatic 
markers of neoplastic progression and one marker of 
relapse after photodynamic therapy.
In The Lancet Oncology, Puya Gharahkhani and 
colleagues from the Barrett’s and Esophageal 
Adenocarcinoma Consortium (BEACON), the Esophageal 
Adenocarcinoma GenEtics Consortium (EAGLE), and the 
Wellcome Trust Case Control Consortium 2 (WTCCC2)10 
report their attempts to systematically prioritise genetic 
loci by doing a meta-analysis of all publicly available 
data from genome-wide association studies. Nine new 
loci were identiﬁ ed from this meta-analysis, which were 
within or near the genes CFTR, MSRA, LINC00208 and 
BLK, KHDRBS2, TPPP and CEP72, TMOD1, SATB2, HTR3C 
and ABCC5, and LPA. Furthermore, for the ﬁ rst time, 
a risk locus speciﬁ c to oesophageal adenocarcinoma 
and independent of risk for Barrett’s oesophagus was 
found—rs9823696, close to HTR3C and ABCC5.
A pathway analysis showed an association of 
these nine loci with muscle-cell diﬀ erentiation, 
which is relevant because Barrett’s oesophagus and 
oesophageal adenocarcinoma are caused proximally 
by defective relaxation of the muscular lower 
oesophageal sphincter. The novel locus with the 
strongest risk for oesophageal adenocarcinoma was 
located within CFTR; mutations within this gene are 
associated with cystic ﬁ brosis. Gastro-oesophageal 
reﬂ ux has been associated with cystic ﬁ brosis and is 
considered part of its phenotypic spectrum. Thus, 
this particular locus is a candidate that potentially 
links two common syndromes previously thought 
to be unrelated. The CFTR protein belongs to the 
ATP-binding cassette (ABC) class of transporters that 
transmits ions across cell membranes; its defective 
function (leaky—ie, permitting defective ion transport) 
is pathogenic in patients with cystic ﬁ brosis. Moreover, 
the risk locus unique to oesophageal adenocarcinoma, 
rs9823696 (close to HTR3C and ABCC5), also encodes 
an ABC-family ion-channel transporter. Thus, these 
two particular associations might link leaky ion 
transport with a leaky lower oesophageal sphincter. 
This association could represent a new area of research 
into the pathogenesis of Barrett’s oesophagus and 
oesophageal adenocarcinoma.
The research by Gharahkhani and colleagues provides 
some much-needed perspective on the wealth of 
data now accumulating in this area of medicine. Even 
if not proven to be disease causing, loci highlighted 
by this study might become valuable, singly or in 
aggregate, for the risk stratiﬁ cation of patients 
with gastro-oesophageal reﬂ ux disorder, Barrett’s 
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Merkel cell carcinoma represents a rare group of 
cutaneous malignancies, which typically develop 
in the sun-damaged skin of elderly individuals 
and often in immunosuppressed patients.1 Locally 
advanced and metastatic Merkel cell carcinoma have 
a grave prognosis, and until recently, the European 
inter-disciplinary consensus-based guidelines recom-
mended clinical trials as a standard of care.2 However, 
in reality, patients with advanced Merkel cell carcinoma 
receive platinum-based chemotherapies, which have a 
limited and short-lived clinical eﬃ  cacy. Chemotherapy 
achieves response rates of up to 50–60% without 
showing a clear survival beneﬁ t. The median overall 
survival noted for treatment with chemotherapy is 
around 9 months.2,3 Complete responses and long-term 
survivors are rare. 
In The Lancet Oncology, Howard Kaufman and 
colleagues4 report results from a phase 2 study in which 
88 patients with advanced Merkel cell carcinoma were 
treated with the PD-L1-blocking antibody avelumab. 
Eight (9%) patients achieved a complete response 
and 20 (23%) patients achieved a partial response.4 
All patients had histologically conﬁ rmed stage IV 
(advanced) disease and had documented progression 
following at least one previous line of chemotherapy 
in the metastatic setting. The median duration of 
response was not reached after a median follow-up 
time of 10 months. Clinical responses were observed 
independently of PD-L1 expression on tumour cells 
or presence of Merkel cell polyomavirus. Tolerability 
of avelumab was excellent, with only one permanent 
treatment discontinuation.4 Two patients discontinued 
treatment because of adverse eﬀ ects.
These results in patients heavily pre-treated with 
chemotherapy indicate that avelumab has a high 
potential to change clinical practice in this aggressive 
cutaneous malignancy and led the US Food and Drug 
Administration to award avelumab a breakthrough 
therapy designation for the treatment of metastatic 
Merkel cell carcinoma in November, 2015. There are 
Checkpoint inhibitors: a new standard of care for advanced 
Merkel cell carcinoma?
oesophagus, or perhaps those at risk of either of these 
two syndromes. In particular, rs9823696 could be useful 
for identifying individuals with Barrett’s oesophagus 
who are at highest risk of developing oesophageal 
adenocarcinoma. Moreover, if one or more of these 
variants prove to have a pathophysiological role in 
Barrett’s oesophagus or oesophageal adenocarcinoma, 
they could become pivotal in the design of novel 
preventative or therapeutic strategies.
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